ACRV
Acrivon Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ACRV
Acrivon Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing oncology medicines that match patients with specific treatments using its proteomics-based platform
480 Arsenal Way, Suite 100, Watertown, Massachusetts 02472
--
Acrivon Therapeutics, Inc., was incorporated in Delaware in March 2018. The Company, a clinical-stage biopharmaceutical company developing precise oncology drugs, utilizes its proprietary proteomics-based Patient Respondent Identification Platform to match them to patients whose tumor predictions are sensitive to each specific drug. The company develops its pipeline of oncology drug candidates by using its proprietary precision drug platform AP3. (The company's AP3 platform enables the creation of drug-specific proprietary OncoSignature companion diagnostics to identify patients most likely to benefit from the company's drug candidates, which the company calls patient responders).
Company Financials
EPS
ACRV has released its 2025 Q3 earnings. EPS was reported at -0.47, versus the expected -0.58, beating expectations. The chart below visualizes how ACRV has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
